SCHEMBL3829425

SCHEMBL3829425

O=S(=O)(Nc1cnc(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl

nearest known ligand 0.77

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.77
CYP3A4 P08684 8/20 0.77
SLC40A1 Q9NP59 2/20 0.53
ALPL P05186 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3825777 0.88 PPARG (0.78) PPARGCYP3A4ALPL
SCHEMBL2742726 0.87 PPARG (1.00) PPARGCYP3A4SLC40A1
SCHEMBL3823799 0.87 PPARG (0.58) PPARGCYP3A4SLC40A1ALPL
SCHEMBL14689431 0.81 PPARG (0.53) PPARGCYP3A4ALPL
SCHEMBL3826366 0.81 PPARG (0.67) PPARGCYP3A4ALPL
SCHEMBL3822856 0.80 PPARG (0.51) PPARGCYP3A4ALPL
SCHEMBL3798202 0.80 PPARG (0.57) PPARGCYP3A4SLC40A1ALPL
SCHEMBL3828690 0.77 PPARG (0.80) PPARGCYP3A4ALPL
Int131 SCHEMBL634767 0.76 PPARG (1.00) PPARGCYP3A4
SCHEMBL3823239 0.76 PPARG (0.66) PPARGCYP3A4ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309786-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Enterprises Limited (IN) 2012-12-06 US claimed
US-20090247574-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Enterprises Limited (IN) 2009-10-01 US claimed
EP-2094687-A1 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Life Sciences Limited (IN) 2009-09-02 EP claimed
WO-2008035306-A1 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS PIRAMAL LIFE SCIENCES LIMITED (IN) 2008-03-27 WO claimed
US-20130040988-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Enterprises Limited (IN) 2013-02-14 US disclosed
US-20120309786-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Enterprises Limited (IN) 2012-12-06 US disclosed
US-8269010-B2 3-amino-pyridine derivatives for the treatment of metabolic disorders PIRAMAL HEALTHCARE LIMITED (IN) 2012-09-18 US disclosed
US-20090247574-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Enterprises Limited (IN) 2009-10-01 US disclosed
EP-2094687-A1 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Piramal Life Sciences Limited (IN) 2009-09-02 EP disclosed
WO-2008035306-A1 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS PIRAMAL LIFE SCIENCES LIMITED (IN) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040988-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS GPR119, ABAT, GOT2 PPARG 69/4885CYP3A4 118/4885SLC40A1 1215/4885
US-20120309786-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS GPR119, ABAT, PYGL PPARG 62/4885CYP3A4 134/4885SLC40A1 1604/4885
US-20090247574-A1 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS GPR119, ABAT, PDXK PPARG 91/4885CYP3A4 207/4885SLC40A1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.